Accumulation of aberrant DNA methylation during colorectal cancer development

World Journal of Gastroenterology

Volumn 20, Issue 4, 2014, Pages 978-987

  Sakai, Eiji ^a,b   Nakajima, Atsushi ^a   Kaneda, Atsushi ^b,c,d  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Aberrant crypt foci; Colorectal adenoma; Colorectal cancer; Colorectal carcinogenesis; DNA methylation; Epigenotype; Genetic mutation

Indexed keywords

ABERRANT CRYPT FOCUS; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; COLORECTAL CANCER; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETIC REPRESSION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; MICROSATELLITE INSTABILITY; PYROSEQUENCING; RISK FACTOR;

ABERRANT CRYPT FOCI; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOGENESIS; DNA METHYLATION; EPIGENOTYPE; GENETIC MUTATION;

ANIMALS; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PHENOTYPE; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893019260     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i4.978     Document Type: Article

References (101)

1. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135: 1079-1099 [PMID: 18773902 DOI: 10.1053/j.gastro.2008.07.076]
2. Kaneda A, Feinberg AP. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res 2005; 65: 11236-11240 [PMID: 16357124 DOI: 10.1158/0008-5472.can-05-2959]
3. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532 [PMID: 2841597 DOI: 10.1056/nejm198809013190901]
4. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B, Hamilton SR. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331: 213-221 [PMID: 8015568 DOI: 10.1056/nejm199407283310401]
5. White RL. Tumor suppressing pathways. Cell 1998; 92: 591-592 [PMID: 9506511]
6. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170 [PMID: 8861899]
7. Dunican DS, McWilliam P, Tighe O, Parle-McDermott A, Croke DT. Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene 2002; 21: 3253-3257 [PMID: 12082642 DOI: 10.1038/sj.onc.1205431]
8. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-241 [PMID: 22700443 DOI: 10.3322/caac.21149]
9. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337 [PMID: 22810696 DOI: 10.1038/nature11252]
10. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158 [PMID: 17344846 DOI: 10.1038/nature05610]
11. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274 [PMID: 16959974 DOI: 10.1126/science.1133427]
12. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, Tollenaar RA, Laird PW. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22: 271-282 [PMID: 21659424 DOI: 10.1101/gr.117523.110]
13. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, Hamilton SR, Issa JP. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007; 104: 18654-18659 [PMID: 18003927 DOI: 10.1073/pnas.0704652104]
14. Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, Isagawa T, Midorikawa Y, Nishimura Y, Sakamoto H, Seto Y, Aburatani H, Kaneda A. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 2010; 16: 21-33 [PMID: 20028768]
15. Yagi K, Takahashi H, Akagi K, Matsusaka K, Seto Y, Aburatani H, Nakajima A, Kaneda A. Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma. Am J Pathol 2012; 180: 616-625 [PMID: 22115708 DOI: 10.1016/j.ajpath.2011.10.010]
16. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692 [PMID: 17320506 DOI: 10.1016/j.cell.2007.01.029]
17. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21 [PMID: 11782440 DOI: 10.1101/gad.947102]
18. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res 2002; 62: 6645-6650 [PMID: 12438262]
19. Kaneda A, Wakazono K, Tsukamoto T, Watanabe N, Yagi Y, Tatematsu M, Kaminishi M, Sugimura T, Ushijima T. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res 2004; 64: 6410-6415 [PMID: 15374948 DOI: 10.1158/0008-5472.can-04-1543]
20. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-8686 [PMID: 10411935]
21. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB, Issa JP. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59: 2307-2312 [PMID: 10344734]
22. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005; 5: 223-231 [PMID: 15719030 DOI: 10.1038/nrc1571]
23. Ushijima T, Morimura K, Hosoya Y, Okonogi H, Tatematsu M, Sugimura T, Nagao M. Establishment of methylationsensitive-representational difference analysis and isolation of hypo-and hypermethylated genomic fragments in mouse liver tumors. Proc Natl Acad Sci USA 1997; 94: 2284-2289 [PMID: 9122186]
24. Gu H, Bock C, Mikkelsen TS, Jäger N, Smith ZD, Tomazou E, Gnirke A, Lander ES, Meissner A. Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. Nat Methods 2010; 7: 133-136 [PMID: 20062050 DOI: 10.1038/nmeth.1414]
25. Hayashi H, Nagae G, Tsutsumi S, Kaneshiro K, Kozaki T, Kaneda A, Sugisaki H, Aburatani H. High-resolution mapping of DNA methylation in human genome using oligonucleotide tiling array. Hum Genet 2007; 120: 701-711 [PMID: 17024368 DOI: 10.1007/s00439-006-0254-6]
26. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 2010; 11: 191-203 [PMID: 20125086 DOI: 10.1038/nrg2732]
27. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, Edsall L, Antosiewicz-Bourget J, Stewart R, Ruotti V, Millar AH, Thomson JA, Ren B, Ecker JR. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009; 462: 315-322 [PMID: 19829295 DOI: 10.1038/nature08514]
28. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schübeler D. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005; 37: 853-862 [PMID: 16007088 DOI: 10.1038/ng1598]
29. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-116 [PMID: 16491070 DOI: 10.1038/nrc1799]
30. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33 [PMID: 16369569 DOI: 10.1038/nrg1748]
31. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom Witzel S, Okano H, Ko MS, Ohlsson R, Longo DL, Feinberg AP. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 2005; 307: 1976-1978 [PMID: 15731405 DOI: 10.1126/science.1108080]
32. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O'Connor T, Ward R. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002; 122: 1376-1387 [PMID: 11984524]
33. Whitehall VL, Wynter CV, Walsh MD, Simms LA, Purdie D, Pandeya N, Young J, Meltzer SJ, Leggett BA, Jass JR. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res 2002; 62: 6011-6014 [PMID: 12414620]
34. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, Barker MA, Arnold S, McGivern A, Matsubara N, Tanaka N, Higuchi T, Young J, Jass JR, Leggett BA. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004; 53: 1137-1144 [PMID: 15247181 DOI: 10.1136/gut.2003.037671]
35. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793 [PMID: 16804544 DOI: 10.1038/ng1834]
36. Samowitz WS. The CpG island methylator phenotype in colorectal cancer. J Mol Diagn 2007; 9: 281-283 [PMID: 17591925]
37. Cheng YW, Pincas H, Bacolod MD, Schemmann G, Giardina SF, Huang J, Barral S, Idrees K, Khan SA, Zeng Z, Rosenberg S, Notterman DA, Ott J, Paty P, Barany F. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res 2008; 14: 6005-6013 [PMID: 18829479 DOI: 10.1158/1078-0432. ccr-08-0216]
38. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007; 132: 127-138 [PMID: 17087942 DOI: 10.1053/j.gastro.2006.09.018]
39. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006; 8: 582-588 [PMID: 17065427 DOI: 10.2353/jmoldx.2006.060082]
40. Burnett-Hartman AN, Newcomb PA, Potter JD, Passarelli MN, Phipps AI, Wurscher MA, Grady WM, Zhu LC, Upton MP, Makar KW. Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res 2013; 73: 2863-2872 [PMID: 23539450 DOI: 10.1158/0008-5472.can-12-3462]
41. Kim YH, Kakar S, Cun L, Deng G, Kim YS. Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps. Int J Cancer 2008; 123: 2587-2593 [PMID: 18798261 DOI: 10.1002/ijc.23840]
42. Maeda T, Suzuki K, Togashi K, Nokubi M, Saito M, Tsujinaka S, Kamiyama H, Konishi F. Sessile serrated adenoma shares similar genetic and epigenetic features with microsatellite unstable colon cancer in a location-dependent manner. Exp Ther Med 2011; 2: 695-700 [PMID: 22977561 DOI: 10.3892/etm.2011.249]
43. O'Brien MJ, Yang S, Mack C, Xu H, Huang CS, Mulcahy E, Amorosino M, Farraye FA. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 2006; 30: 1491-1501 [PMID: 17122504 DOI: 10.1097/01.pas.0000213313.36306.85]
44. Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, Goldblum JR, Guillem JG, Kahi CJ, Kalady MF, O'Brien MJ, Odze RD, Ogino S, Parry S, Snover DC, Torlakovic EE, Wise PE, Young J, Church J. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012; 107: 1315-129; quiz 1314, 1330 [PMID: 22710576 DOI: 10.1038/ajg.2012.161]
45. Vaughn CP, Wilson AR, Samowitz WS. Quantitative evaluation of CpG island methylation in hyperplastic polyps. Mod Pathol 2010; 23: 151-156 [PMID: 19855373 DOI: 10.1038/modpathol.2009.150]
46. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010; 29: 181-206 [PMID: 20135198 DOI: 10.1007/s10555-010-9207-6]
47. Qi J, Zhu YQ, Luo J, Tao WH. Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol 2006; 12: 7113-7117 [PMID: 17131472]
48. Kudo S, Kashida H, Nakajima T, Tamura S, Nakajo K. Endoscopic diagnosis and treatment of early colorectal cancer. World J Surg 1997; 21: 694-701 [PMID: 9276699]
49. Minamoto T, Sawaguchi K, Mai M, Yamashita N, Sugimura T, Esumi H. Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas. Cancer Res 1994; 54: 2841-2844 [PMID: 8187064]
50. Minamoto T, Sawaguchi K, Ohta T, Itoh T, Mai M. Superficial-type adenomas and adenocarcinomas of the colon and rectum: a comparative morphological study. Gastroenterology 1994; 106: 1436-1443 [PMID: 8194688]
51. Tada S, Iida M, Matsumoto T, Yao T, Aoyagi K, Koga H, Tanoue Y, Fujishima M. Small flat cancer of the rectum: clinicopathologic and endoscopic features. Gastrointest Endosc 1995; 42: 109-113 [PMID: 7590044]
52. Watari J, Saitoh Y, Obara T, Fujiya M, Maemoto A, Ayabe T, Ashida T, Yokota K, Orii Y, Kohgo Y. Natural history of colorectal nonpolypoid adenomas: a prospective colonoscopic study and relation with cell kinetics and K-ras mutations. Am J Gastroenterol 2002; 97: 2109-2115 [PMID: 12190185 DOI: 10.1111/j.1572-0241.2002.05931.x]
53. Muto T, Kamiya J, Sawada T, Konishi F, Sugihara K, Kubota Y, Adachi M, Agawa S, Saito Y, Morioka Y. Small "flat adenoma" of the large bowel with special reference to its clinicopathologic features. Dis Colon Rectum 1985; 28: 847-851 [PMID: 4053897]
54. Soetikno R, Friedland S, Kaltenbach T, Chayama K, Tanaka S. Nonpolypoid (flat and depressed) colorectal neoplasms. Gastroenterology 2006; 130: 566-576; quiz 588-589 [PMID: 16472608 DOI: 10.1053/j.gastro.2005.12.006]
55. Testoni PA, Notaristefano C, Vailati C, Di Leo M, Viale E. High-definition colonoscopy with i-Scan: better diagnosis for small polyps and flat adenomas. World J Gastroenterol 2012; 18: 5231-5239 [PMID: 23066318 DOI: 10.3748/wjg.v18. i37.5231]
56. Morita T, Tomita N, Ohue M, Sekimoto M, Yamamoto H, Ohnishi T, Tada M, Ikenaga M, Miyake Y, Sakita I, Tamaki Y, Matsuura N, Ito M, Monden M. Molecular analysis of diminutive, flat, depressed colorectal lesions: are they precursors of polypoid adenoma or early stage carcinoma? Gastrointest Endosc 2002; 56: 663-671 [PMID: 12397273 DOI: 10.1067/mge.2002.129087]
57. Saitoh Y, Waxman I, West AB, Popnikolov NK, Gatalica Z, Watari J, Obara T, Kohgo Y, Pasricha PJ. Prevalence and distinctive biologic features of flat colorectal adenomas in a North American population. Gastroenterology 2001; 120: 1657-1665 [PMID: 11375947]
58. Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, Jaramillo E, Rubio C, Koizumi K, Hirakawa K, Boland CR. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res 2001; 61: 2676-2683 [PMID: 11289147]
59. Kinney TP, Merel N, Hart J, Joseph L, Waxman I. Microsatellite analysis of sporadic flat and depressed lesions of the colon. Dig Dis Sci 2005; 50: 327-330 [PMID: 15745095]
60. Rembacken BJ, Fujii T, Cairns A, Dixon MF, Yoshida S, Chalmers DM, Axon AT. Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. Lancet 2000; 355: 1211-1214 [PMID: 10770302]
61. Hiraoka S, Kato J, Tatsukawa M, Harada K, Fujita H, Morikawa T, Shiraha H, Shiratori Y. Laterally spreading type of colorectal adenoma exhibits a unique methylation phenotype and K-ras mutations. Gastroenterology 2006; 131: 379-389 [PMID: 16890591 DOI: 10.1053/j.gastro.2006.04.027]
62. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339: 1277-1284 [PMID: 9791143 DOI: 10.1056/nejm199810293391803]
63. Shpitz B, Bomstein Y, Mekori Y, Cohen R, Kaufman Z, Neufeld D, Galkin M, Bernheim J. Aberrant crypt foci in human colons: distribution and histomorphologic characteristics. Hum Pathol 1998; 29: 469-475 [PMID: 9596270]
64. Adler DG, Gostout CJ, Sorbi D, Burgart LJ, Wang L, Harmsen WS. Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest Endosc 2002; 56: 657-662 [PMID: 12397272 DOI: 10.1067/mge.2002.128540]
65. Hurlstone DP, Karajeh M, Sanders DS, Drew SK, Cross SS. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia. Am J Gastroenterol 2005; 100: 1283-1289 [PMID: 15929758 DOI: 10.1111/j.1572-0241.2005.40891.x]
66. Kim J, Ng J, Arozulllah A, Ewing R, Llor X, Carroll RE, Benya RV. Aberrant crypt focus size predicts distal polyp histopathology. Cancer Epidemiol Biomarkers Prev 2008; 17: 1155-1162 [PMID: 18483337 DOI: 10.1158/1055-9965.epi-07-2731]
67. Moxon D, Raza M, Kenney R, Ewing R, Arozullah A, Mason JB, Carroll RE. Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population. Clin Gastroenterol Hepatol 2005; 3: 271-278 [PMID: 15765447]
68. Rudolph RE, Dominitz JA, Lampe JW, Levy L, Qu P, Li SS, Lampe PD, Bronner MP, Potter JD. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 2005; 14: 605-608 [PMID: 15767337 DOI: 10.1158/1055-9965. epi-04-0058]
69. Sakai E, Takahashi H, Kato S, Uchiyama T, Hosono K, Endo H, Maeda S, Yoneda M, Taguri M, Nakajima A. Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm. Cancer Epidemiol Biomarkers Prev 2011; 20: 1918-1924 [PMID: 21750169 DOI: 10.1158/1055-9965.epi-11-0104]
70. Seike K, Koda K, Oda K, Kosugi C, Shimizu K, Nishimura M, Shioiri M, Takano S, Ishikura H, Miyazaki M. Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms. Am J Gastroenterol 2006; 101: 1362-1369 [PMID: 16771962 DOI: 10.1111/j.1572-0241.2006.00578.x]
71. Stevens RG, Swede H, Heinen CD, Jablonski M, Grupka M, Ross B, Parente M, Tirnauer JS, Giardina C, Rajan TV, Rosenberg DW, Levine J. Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Lett 2007; 248: 262-268 [PMID: 16950561 DOI: 10.1016/j.canlet.2006.08.003]
72. Uchiyama T, Takahashi H, Endo H, Kato S, Sakai E, Hosono K, Yoneda M, Inamori M, Hippo Y, Nakagama H, Nakajima A. Number of aberrant crypt foci in the rectum is a useful surrogate marker of colorectal adenoma recurrence. Dig Endosc 2012; 24: 353-357 [PMID: 22925289 DOI: 10.1111/j.1443-1661.2012.01289.x]
73. Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 2008; 1: 21-31 [PMID: 19138933 DOI: 10.1158/1940-6207.capr-07-0011]
74. Higurashi T, Hosono K, Endo H, Takahashi H, Iida H, Uchiyama T, Ezuka A, Uchiyama S, Yamada E, Ohkubo H, Sakai E, Maeda S, Morita S, Natsumeda Y, Nagase H, Nakajima A. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial. BMC Cancer 2012; 12: 413 [PMID: 22992267 DOI: 10.1186/1471-2407-12-413]
75. Higurashi T, Takahashi H, Endo H, Hosono K, Yamada E, Ohkubo H, Sakai E, Uchiyama T, Hata Y, Fujisawa N, Uchiyama S, Ezuka A, Nagase H, Kessoku T, Matsuhashi N, Yamanaka S, Inayama Y, Morita S, Nakajima A. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer 2012; 12: 118 [PMID: 22443173 DOI: 10.1186/1471-2407-12-118]
76. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H, Nakajima A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010; 3: 1077-1083 [PMID: 20810669 DOI: 10.1158/1940-6207. capr-10-0186]
77. Takayama T, Nagashima H, Maeda M, Nojiri S, Hirayama M, Nakano Y, Takahashi Y, Sato Y, Sekikawa H, Mori M, Sonoda T, Kimura T, Kato J, Niitsu Y. Randomized doubleblind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. Clin Cancer Res 2011; 17: 3803-3811 [PMID: 21385928 DOI: 10.1158/1078-0432.ccr-10-2395]
78. Sakai E, Morioka T, Yamada E, Ohkubo H, Higurashi T, Hosono K, Endo H, Takahashi H, Takamatsu R, Cui C, Shiozawa M, Akaike M, Samura H, Nishimaki T, Nakajima A, Yoshimi N. Identification of preneoplastic lesions as mucindepleted foci in patients with sporadic colorectal cancer. Cancer Sci 2012; 103: 144-149 [PMID: 22017323 DOI: 10.1111/j.1349-7006.2011.02125.x]
79. Takayama T, Ohi M, Hayashi T, Miyanishi K, Nobuoka A, Nakajima T, Satoh T, Takimoto R, Kato J, Sakamaki S, Niitsu Y. Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 2001; 121: 599-611 [PMID: 11522744]
80. Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR, Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 2002; 160: 1823-1830 [PMID: 12000733 DOI: 10.1016/s0002-9440(10)61128-5]
81. Otori K, Konishi M, Sugiyama K, Hasebe T, Shimoda T, Kikuchi-Yanoshita R, Mukai K, Fukushima S, Miyaki M, Esumi H. Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of human colon tissue. Cancer 1998; 83: 896-900 [PMID: 9731892]
82. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 686-700 [PMID: 22009203 DOI: 10.1038/nrgastro.2011.173]
83. Rosenberg DW, Yang S, Pleau DC, Greenspan EJ, Stevens RG, Rajan TV, Heinen CD, Levine J, Zhou Y, O'Brien MJ. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res 2007; 67: 3551-3554 [PMID: 17440063 DOI: 10.1158/0008-5472.can-07-0343]
84. Ahuja N, Issa JP. Aging, methylation and cancer. Histol Histopathol 2000; 15: 835-842 [PMID: 10963127]
85. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7: 536-540 [PMID: 7951326 DOI: 10.1038/ng0894-536]
86. Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 1999; 9: 349-357 [PMID: 10547343 DOI: 10.1006/scbi.1999.0135]
87. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-968 [PMID: 13094644]
88. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36: 417-422 [PMID: 15034581 DOI: 10.1038/ng1330]
89. Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Grieu F, Watanabe G, Iacopetta B. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer 2006; 94: 593-598 [PMID: 16421593 DOI: 10.1038/sj.bjc.6602940]
90. Belshaw NJ, Elliott GO, Foxall RJ, Dainty JR, Pal N, Coupe A, Garg D, Bradburn DM, Mathers JC, Johnson IT. Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br J Cancer 2008; 99: 136-142 [PMID: 18542073 DOI: 10.1038/sj.bjc.6604432]
91. Hiraoka S, Kato J, Horii J, Saito S, Harada K, Fujita H, Kuriyama M, Takemoto K, Uraoka T, Yamamoto K. Methylation status of normal background mucosa is correlated with occurrence and development of neoplasia in the distal colon. Hum Pathol 2010; 41: 38-47 [PMID: 19733896 DOI: 10.1016/j.humpath.2009.06.002]
92. Silviera ML, Smith BP, Powell J, Sapienza C. Epigenetic differences in normal colon mucosa of cancer patients suggest altered dietary metabolic pathways. Cancer Prev Res (Phila) 2012; 5: 374-384 [PMID: 22300984 DOI: 10.1158/1940-6207. capr-11-0336]
93. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-1549 [PMID: 18479499 DOI: 10.1111/j.1572-0241.2008.01875.x]
94. Mori Y, Olaru AV, Cheng Y, Agarwal R, Yang J, Luvsanjav D, Yu W, Selaru FM, Hutfless S, Lazarev M, Kwon JH, Brant SR, Marohn MR, Hutcheon DF, Duncan MD, Goel A, Meltzer SJ. Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer 2011; 18: 465-478 [PMID: 21636702 DOI: 10.1530/erc-11-0083]
95. Simmer F, Brinkman AB, Assenov Y, Matarese F, Kaan A, Sabatino L, Villanueva A, Huertas D, Esteller M, Lengauer T, Bock C, Colantuoni V, Altucci L, Stunnenberg HG. Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics 2012; 7: 1355-1367 [PMID: 23079744 DOI: 10.4161/epi.22562]
96. Yi JM, Dhir M, Guzzetta AA, Iacobuzio-Donahue CA, Heo K, Yang KM, Suzuki H, Toyota M, Kim HM, Ahuja N. DNA methylation biomarker candidates for early detection of colon cancer. Tumour Biol 2012; 33: 363-372 [PMID: 22238052 DOI: 10.1007/s13277-011-0302-2]
97. Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, Butz ML, Thibodeau SN, Rabeneck L, Paszat LF, Kinzler KW, Vogelstein B, Bjerregaard NC, Laurberg S, Sørensen HT, Berger BM, Lidgard GP. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012; 142: 248-56; quiz e25-6 [PMID: 22062357 DOI: 10.1053/j.gastro.2011.10.031]
98. Tóth K, Sipos F, Kalmár A, Patai AV, Wichmann B, Stoehr R, Golcher H, Schellerer V, Tulassay Z, Molnár B. Detection of methylated SEPT9 in plasma is a reliable screening method for both left-and right-sided colon cancers. PLoS One 2012; 7: e46000 [PMID: 23049919 DOI: 10.1371/journal. pone.0046000]
99. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618 [PMID: 15659508 DOI: 10.1200/jco.2005.01.086]
100. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP. Addition of cetuximab to oxaliplatin-based firstline combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114 [PMID: 21641636 DOI: 10.1016/s0140-6736(11)60613-2]
101. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096 [PMID: 19188670]